01 / Mechanism

Small molecule, same receptor.

Orforglipron is a low-molecular-weight (~570 Da) non-peptide agonist at the GLP-1 (glucagon-like peptide-1) receptor. It binds at a site allosteric to the orthosteric peptide-binding pocket and biases downstream signaling toward G-protein activation, with relatively reduced β-arrestin recruitment [Kawai 2020]. The biochemistry of a small molecule rather than a 30-residue peptide is what enables every practical difference from semaglutide and liraglutide.

Three consequences follow. First, no gastric proteolysis, so no need for the SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) permeation-enhancer formulation Rybelsus uses, and no need for the strict fasted-window administration that limits its absorption. Second, predictable oral pharmacokinetics — half-life ~29–49 hours across the dose range, supporting clean once-daily dosing with minimal food effect [Frias 2023]. Third, fermentation- and bioreactor-free synthesis: orforglipron can be manufactured by standard small-molecule chemistry at a fraction of the cost and capacity required for peptide bulk drug substance.

That last point is the strategic story. Semaglutide and tirzepatide have been supply-constrained almost since launch. A small molecule can be made in tablet form in vastly greater volume — both at lower manufacturing cost and faster to scale geographically. See the long read on the GLP-1 era for how the next-generation pipeline reshapes access.

02 / Expected dosing

Phase 3 schedule.

Step	Oral dose	Indication	Note
Step 1	3 mg once daily	Initiation	4 weeks — tolerance dose
Step 2	6 mg once daily	Titration	4 weeks
Step 3	12 mg once daily	Titration	4 weeks
Step 4	24 mg once daily	T2D maintenance	ACHIEVE-1 low-target
Step 5	36 mg once daily	Obesity / T2D high-target	ATTAIN-1 top dose

Phase 3 readouts (2025)

ATTAIN-1 (obesity, no T2D, 72 weeks): −12.4% body weight at 36 mg; 59.6% achieved ≥10% loss and 39.6% achieved ≥15% loss [ATTAIN-1 2025]. ATTAIN-2 (obesity + T2D, 72 weeks): −10.5% body weight at top dose with −1.8% HbA1c [ATTAIN-2 2025]. ACHIEVE-1 (T2D, 40 weeks): HbA1c down 1.3–1.6% across doses, weight down ~7.9% at top dose. Food-independent dosing was a registration endpoint and was met.

03 / Expected contraindications

Likely label restrictions.

Personal or family history of medullary thyroid carcinoma (MTC). Class effect for all GLP-1 RAs based on rodent C-cell hyperplasia.
Multiple endocrine neoplasia syndrome type 2 (MEN 2). Same rationale.
Prior pancreatitis. Relative contraindication — class label effect.
Severe gastroparesis. Drug worsens motility.
Pregnancy. Discontinue 1–2 months before planned conception (shorter washout than weekly peptides).
Severe hepatic impairment. Limited Phase 3 data in Child-Pugh C; dose adjustment likely required.

04 / Side effects

What Phase 3 showed.

Nausea (~14–25% across doses). Class-typical and dose-dependent. Generally milder than injectable GLP-1s at equivalent receptor occupancy, likely because oral PK has a smoother curve.
Diarrhea, constipation, vomiting. Same profile as the peptide GLP-1s.
Mild ALT/AST elevation. Reported in earlier Phase 2 data, mostly transient and asymptomatic; no signal of clinically meaningful hepatotoxicity in Phase 3.
Lipase elevations (asymptomatic). Class effect; no excess clinical pancreatitis vs placebo in trials to date.
Heart rate increase (~2–3 bpm). Class-typical.
Hypoglycemia. Rare as monotherapy in non-diabetics; expected in combination with sulfonylureas / insulin.

05 / Positioning and manufacturing

Why this molecule matters.

Orforglipron's clinical efficacy is real but not class-leading — at 36 mg it lands roughly between high-dose liraglutide and 2.4 mg semaglutide on weight. Tirzepatide and retatrutide will still be the maximum-effect choices for patients who need them. What orforglipron changes is access:

No injection. A meaningful subset of patients refuse GLP-1 therapy because of needles; a tablet removes that barrier entirely.
No fasted-window protocol. Rybelsus requires 30 minutes fasted with at most 4 oz water before the first food of the day. Adherence is poor in real-world data. Orforglipron is taken with or without food, any time.
No cold-chain logistics. Peptides need refrigerated distribution; small-molecule tablets are room-temperature-stable and distribute through normal pharmacy channels — including to low- and middle-income markets.
Manufacturing scale. Small-molecule chemical synthesis can be ramped in months rather than the years required for bioreactor capacity. Lilly has indicated multi-billion-tablet annual capacity at launch.

Lilly has guided that obesity submission will occur by end-2025 and T2D submission in 2026, with launch in 2026–2027. Pricing strategy is the open question — small-molecule cost-of-goods is far lower than peptide manufacturing, but Lilly has no incentive to undercut tirzepatide pricing. Realistic launch positioning: parity with Wegovy/Zepbound list price, broader payer coverage, and significant patient-assistance penetration in emerging markets.

06 / Cost (anticipated)

What it will likely cost.

Source	Form	~Monthly cost (USD)	Note
Brand (anticipated)	Once-daily tablet	$900–$1,300	Parity with peptide GLP-1 list pricing
Brand (anticipated, insured)	Once-daily tablet	$25–$100 copay	If covered for obesity
Brand (anticipated, emerging markets)	Once-daily tablet	$50–$200	Tiered pricing likely
Cost of goods (estimated)	Active ingredient	< $5/month	Industry estimates for small-molecule API

Cost-of-goods analysis is what makes orforglipron strategically important: when patents expire in the 2030s, generic small-molecule GLP-1 therapy could plausibly drop below $20/month — orders of magnitude cheaper than any current peptide GLP-1.

07 / Key references

The evidence base.

Kawai T et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. PNAS. 2020;117(47):29959–29967. [Kawai 2020]
Frias JP et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472–483. [Frias 2023]
Wharton S et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. NEJM. 2023;389(10):877–888. [Wharton 2023]
Eli Lilly. ATTAIN-1: Orforglipron Phase 3 results in obesity without type 2 diabetes (72 weeks). Published in NEJM 2025. [ATTAIN-1 2025]
Aronne LJ et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025. [ATTAIN-2 2025]
Eli Lilly. ACHIEVE-1, ACHIEVE-2, ACHIEVE-5: Phase 3 type 2 diabetes program readouts. 2025 press releases. [ACHIEVE 2025]

About this profile

Last reviewed against evidence: 2026-05-12. This profile is editorial reference content, not sponsored. Wellness Radar does not run affiliate links on prescription drugs. Orforglipron is investigational as of May 2026 and not commercially available outside clinical trials. Educational reference — not a prescription.

Orforglipron